Journal of Liver

Metabolic dysfunction associated fatty liver disease & diabetes

14^th International Conference on Liver Diseases & Hepatology

May 18, 2023 | Webinar

Joseph M Pappachan

Manchester Metropolitan University, UK

Scientific Tracks Abstracts: J Liver

Abstract:

The global obesity pandemic has resulted in significant increase in the prevalence of metabolic syndrome (MetS) across the world. Several MetS-related diseases including hypertension, dyslipidemia, type 2 diabetes mellitus (T2DM) and metabolic-associated fatty live disease (MAFLD), have increased as a consequence, and resulted in a substantial increase in morbidity and mortality from these noncommunicable disease in the past 2 decades of 21st century and continue its toll even today. Because of the similarity in pathobiology, T2DM and MAFLD coexist in many patients and potentiate the disease-related outcomes for both diseases with accelerated progression and worse complications of the individual disorders. It is crucial to understand this mutually interconnected diseases for optimal management by both hepatologists and diabetologists for planning optimal management strategies. A wholistic approach with an appropriate multidisciplinary team involving both the specialists and, when necessary, liaising with dieticians and surgeons is important for appropriate management. Some of the antidiabetic medications including insulin can worsen obesity and diabesity (obesity-related diabetes) and are not ideal for patients with MAFLD which is often overlooked by diabetologists while attempting to control diabetes. As the current management of MAFLD is mostly lifestyle changes including dietary adjustments and exercises in the absence of approved and effective pharmacotherapy, more research is needed for development of new drug molecules. Several of the measures to control T2DM can be effectively used for appropriate care of MAFLD especially when the diseases coexist. However, many physicians are not aware of the best strategy for these kinds of patients. Therefore, a comprehensive guidance to treating physicians with best evidence is important from a diabetologist’s perspective on the management of MAFLD. This is an attempt to elaborate the best practice pearls with an up-to-date review of current literature.

Biography :

Professor Joseph M Pappachan is a senior consultant Endocrinologist from the UK and honorary professor at the Manchester Metropolitan University. He is associate editor to Frontiers in Clinical Diabetes, World Journal of Diabetes & TouchREVIEWS in Endocrinology, and section editor (endo & Metab) to Current Drug Safety. He has edited an issue on MAFLD recently in Endocrinology & Metabolism Clinics of North America. He is also in the EB of JCEM Case report and is the lead editor the Elsevier Textbook on Endocrine Hypertension. He is the research head to his hospital endocrine division and has procured £ 3 million research grant with his colleagues. He has 130 scientific publications in peer reviewed journals and has multinational research collaborations. His research special interests include obesity, metabolic disorders including MAFLD, neuroendocrinology & parathyroid disorders.